scholarly journals A systemic literature review of the effect of proton pump inhibitors on gallbladder function

2020 ◽  
Vol 5 (1) ◽  
pp. e000227
Author(s):  
Mamoona Javed ◽  
Muhammad Saad Tanveer ◽  
Muhammad Hassan Tanveer ◽  
Muhammad Hayder Ali
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Systematic Search ◽  
Exclusion Criterion ◽  
Inclusion Criteria ◽  
Gallbladder Function ◽  
The Common ◽  
Potential Impact ◽  
Abstract Screening ◽  
Full Text Screening

Objective: To determine the association between proton pump inhibitors and gallbladder function Methods: A systematic search of Medline, Embase and CENTRAL (inception to April 2020) was conducted to capture the relevant studies. A comprehensive inclusion-exclusion criterion was developed and implemented to screen the titles and abstracts. . We, however, found no eligible studies. Results: The systematic search identified 38 unique articles for title and abstract screening. Of which, five were included as potentially relevant studies. However, upon full-text screening, none of them met our inclusion criteria. This review is, therefore, an empty systematic review. Conclusion: There are no good quality studies determining the effect of proton pump inhibitors on gallbladder function. Given the common use of proton pump inhibitors and their potential impact on gallbladder function, there is an urgent need for conducting clinical studies to address this gap in the evidence.

scholarly journals Long-term proton pump inhibitor use and the incidence of gastric cancer: A systematic review and meta-analysis

2020 ◽  
Vol 2 (1) ◽  
pp. 1-11
Author(s):  
Ju-Li Lin ◽  
Jian-Xian Lin ◽  
Chao-Hui Zheng ◽  
Jian-Wei Xie ◽  
Jia-bin Wang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Systematic Review ◽  
Proton Pump Inhibitor ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Meta Analysis ◽  
Inclusion Criteria ◽  
Risk Ratios

Background: There are controverted whether the long-term use of proton pump inhibitors (PPI) will increase the risk of gastric cancer. We performed a meta-analysis to assess the risk of gastric cancer in PPI users compared with non-PPI users. Methods: The main inclusion criteria were original studies reporting the incidence of gastric cancer in PPI users compared with non-PPI users. Key outcomes were the risk ratios (RR) for gastric cancer in association with PPI users or non-PPI users. Results: We analyzed data from 8 studies, comprising more than 927,684 patients. The risk of gastric cancer in PPI users was significantly higher than in non-PPI users [RR= 2.10, 95% CI (1.17-3.97)]. The risk of gastric cancer was similar between the 2 groups when the duration was ≤1 year [RR= 2.18, 95% CI (0.66-7.11)]. While the risk of gastric cancer for PPI users was higher than in non-PPI users when the duration was between 1-3 years, ≥1 year, ≥3 years and ≥5 years. The risk of non-cardiac gastric cancer for PPI users was higher than for non-PPI users [RR= 2.66, 95% CI (1.66 -4.27)], and the risk of non-cardiac gastric cancer for PPI users was higher than for non-PPI users when the duration ≥1 year [RR= 1.99, 95% CI (1.03-3.83)], but the risk for cardiac gastric cancer was similar between the 2 groups [RR= 1.86, 95% CI (0.71-4.89)]. Conclusions: We found the long-term use of PPI (duration ≥1 year) was significantly associated with a higher risk of non-cardiac gastric cancer.

Proton pump inhibitors reduce gallbladder function

2006 ◽  
Vol 20 (9) ◽  
pp. 1364-1367 ◽  
Author(s):  
M. A. Cahan ◽  
L. Balduf ◽  
K. Colton ◽  
B. Palacioz ◽  
W. McCartney ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Gallbladder Function

scholarly journals The Positive Association between Proton Pump Inhibitors and Clostridium Difficile Infection

2021 ◽  
Vol 12 (1) ◽  
pp. 21
Author(s):  
Dania Tawam ◽  
Michael Baladi ◽  
Paiboon Jungsuwadee ◽  
Grace Earl ◽  
Jayoung Han
Keyword(s):  
Clostridium Difficile ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Systematic Reviews ◽  
Positive Association ◽  
Inclusion Criteria ◽  
Over The Counter ◽  
Search Terms ◽  
The Us ◽  
Meta Analyses

Background: Proton pump inhibitors (PPIs) are among the most commonly used medications by patients due to its availability over the counter and frequent prescribing by physicians to treat and alleviate symptoms of gastroesophageal reflux disease. Recently, the FDA issued a warning with respect to the utilization of PPIs and risk of developing Clostridium difficile infections (CDI). The most commonly known medications to cause CDI are antibiotics. However, available studies suggest an association and increase in risk for CDI with PPI use as well. Objective: The purpose of this research is to review and summarize data currently available on the association between PPIs and CDI. Methods: To search for eligible studies, EBSCO engines were investigated using proton pump inhibitors or PPIs and Clostridium difficile or C. diff. as search terms. Meta analyses and systematic reviews published between 2000 and 2020 on adult patients were considered. Results: Eight meta-analyses and systematic reviews met the inclusion criteria. They included studies conducted in the US, Europe, Asia and Canada on inpatient and outpatient adults. The final result for all 8 studies showed a statistically significant association between PPIs and CDI ranging from mild to high risk. Conclusion: Currently available data suggest a positive association between PPIs and CDI.

scholarly journals The relationship between the combined use of various proton pump inhibitors with antiplatelet drugs and the risk of cardiovascular complications

2019 ◽  
Vol 91 (8) ◽  
pp. 118-126 ◽  
Author(s):  
O D Ostroumova ◽  
A I Kochetkov ◽  
A P Pereverzev ◽  
E V Kravchenko ◽  
A N Kazjulin ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Drug Interactions ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Cardiovascular Events ◽  
Cardiovascular Complications ◽  
Inclusion Criteria ◽  
Combined Use ◽  
Meta Analyses ◽  
The Relationship

In the article the problem of the combined use of clopidogrel and various proton pump inhibitors (PPIs) in terms of cardiovascular complications risk and stent thrombosis is considered. The results of meta - analyses and a systematic reviews affecting this issue are represented in detail. The inter - drug interactions mechanisms of various PPIs with clopidogrel based on the characteristics of the metabolism in the liver cytochromes system are discussed. The authors conducted a search, systematization and analysis of studies regarding the association between cardiovascular risk and combined use of individual medications from PPI class with clopidogrel, and these results are presented in the review. Currently available data do not allow to answer the question about the differences between individual PPIs in their impact on the risk of adverse cardiovascular events due to the small number of such studies, design heterogeneity, differences in the inclusion criteria and end points as well as in the rate of administration of individual PPIs.

Abstract 3998: Proton Pump Inhibitors Effect on Clopidogrel Effectiveness: The Clopidogrel Medco Outcomes Study

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Ronald E Aubert ◽  
Robert S Epstein ◽  
J R Teagarden ◽  
Fang Xia ◽  
Jianying Yao ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Stent Placement ◽  
Adverse Outcomes ◽  
Coronary Artery Stent ◽  
Cytochrome P450 2C19 ◽  
Potential Impact ◽  
One Year ◽  
The One

Background: The anti-platelet properties of clopidogrel are thought to be activated by cytochrome P450 2C19. This isoenzyme is potently inhibited by the most commonly prescribed proton pump inhibitors (PPIs) and therefore may interfere with clopidogrel activation and its anti-platelet effects. Methods: We investigated the potential impact of PPIs on the effectiveness of clopidogrel to prevent coronary artery stent re-stenosis through a retrospective cohort study using the National Medco Integrated Database file, which covers approximately 19 million lives. We selected patients who underwent stent placement at sometime during a one-year period in 2005–2006, who started taking clopidogrel at the time of stent placement, and who were at least 80% compliant during the ensuing year (n=14,383). We followed these patients for the one-year incidence of major adverse CV events: hospitalization for stroke, MI, angina or CABG. We compared those who took clopidogrel alone (n=9862) vs. those who took clopidogrel with PPIs (n=4521), adjusting for baseline differences in age, gender and comorbidity. Results: Stent patients with no preceding CV events taking PPIs with clopidogrel showed a 32.5% incidence of a major CV event within one year vs. 21.2% of patients not taking PPIs (adjusted OR 1.79, CI 1.62–1.97). A more pronounced effect was seen among patients with a preceding CV event; 39.8% vs 26.2% (adjusted OR of 1.86, CI 1.63–2.12). Conclusions: Our findings suggest that the drug interaction between PPIs and clopidogrel may result in serious adverse outcomes within one year of therapy initiation, and further support investigations into the effects of cytochrome P450 2C19 genetic polymorphisms.

scholarly journals Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients

2020 ◽  
Vol 21 (7) ◽  
pp. 431-441
Author(s):  
Rachel M Black ◽  
Alexis K Williams ◽  
Lindsay Ratner ◽  
Daniel J Crona ◽  
Tim Wiltshire ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Antiplatelet Therapy ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Real World ◽  
Simulation Analysis ◽  
Coronary Intervention ◽  
Cyp2c19 Genotype ◽  
Percutaneous Coronary ◽  
Potential Impact

Aim: CYP2C19 genotyping is used to guide antiplatelet therapy after percutaneous coronary intervention (PCI). This study evaluated the potential impact of CYP2C19 and multigene pharmacogenomics (PGx) testing on medications beyond antiplatelet therapy in a real-world cohort of PCI patients that underwent CYP2C19 testing. Methodology & results: Multiple medications with actionable PGx recommendations, including proton pump inhibitors, antidepressants and opioids, were commonly prescribed. Approximately 50% received a CYP2C19 metabolized medication beyond clopidogrel and 7% met criteria for a CYP2C19 genotype-guided intervention. A simulation analysis projected that 17.5 PGx-guided medication interventions per 100 PCI patients could have been made if multigene PGx results were available. Conclusion: This suggests that CYP2C19 and multigene PGx results could be used to optimize medication prescribing beyond antiplatelet therapy in PCI patients.

Inhibitory effect of proton pump inhibitors against chemotaxis of Helicobacter pylori

2001 ◽  
Vol 120 (5) ◽  
pp. A655-A656
Author(s):  
H NAKAMURA ◽  
H YOSHIYAMA ◽  
H YANAI ◽  
M SHIRAL ◽  
T NAKAZAWA ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Inhibitory Effect

Abstract #728: Severe Hypomagnesemia and Breakthrough Seizure with Proton Pump Inhibitors Use

2015 ◽  
Vol 21 ◽  
pp. 139
Author(s):  
Muhammad Mahmood ◽  
Andrew Kinch ◽  
Woodall Brittany ◽  
Ayman Elkadry
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Breakthrough Seizure

Abstract #713 Proton Pump Inhibitors and Hypocalcemia: Does it Really Happen?

2018 ◽  
Vol 24 ◽  
pp. 157-158
Author(s):  
Franco Vallejo Garcia ◽  
Melissa Sum
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump

Erratum: Overutilization of Proton Pump Inhibitors: A Review of Cost-Effectiveness and Risk in PPI

2009 ◽  
Vol 104 (4) ◽  
pp. 1072-1072
Author(s):  
Joel J Heidelbaugh ◽  
Kathleen L Goldberg ◽  
John M Inadomi
Keyword(s):  
Cost Effectiveness ◽  
Proton Pump Inhibitors ◽  
Proton Pump
Sign in / Sign up

Export Citation Format

Share Document